Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Piechocki, M. P.
Right arrow Articles by Yoo, G. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Piechocki, M. P.
Right arrow Articles by Yoo, G. H.
Clinical Cancer Research Vol. 8, 870-877, March 2002
© 2002 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Anticancer Activity of Docetaxel in Murine Salivary Gland Carcinoma1

Marie P. Piechocki2, Fulvio Lonardo, John F. Ensley, Tam Nguyen, Harold Kim and George H. Yoo

Departments of Otolaryngology-Head and Neck Surgery [M. P. P., T. N., G. H. Y.] and Radiation Oncology [H. K.] and Department of Medicine, Division of Hematology/Oncology [J. F. E.], Wayne State University and Karmanos Cancer Institute, Detroit, Michigan 48201, and Department of Pathology, Wayne State University, Detroit, Michigan 48201 [F. L.]

Purpose: The purpose of this study was to evaluate the biological mechanisms of docetaxel (TXT) on salivary gland carcinoma.

Experimental Design: The effects of TXT on a spontaneous murine salivary carcinoma were determined. Proliferation, cell cycle regulation, connexin43 expression, gap-junctional intercellular communication, apoptosis, and Fas receptor (FasR) expression were measured.

Results: We characterized a spontaneous mouse salivary gland carcinoma (SGC1). SGC1 is a poorly differentiated carcinoma that originated from the parotid gland of a BALB/c mouse. SGC1 cells were cultured and found to be immortal past 30 passages. Initially, cells formed tumor nodules in severe combined immunodeficient (SCID) mice. Afterward, SGC1 cells that were subcultured from SCID tumors readily formed colonies in soft agar and were highly tumorigenic in SCID mice and immune-competent BALB/c hosts. Dose response for TXT with respect to growth suppression, G2-M cell cycle arrest, and apoptosis was found. Induction of apoptosis by TXT coincided with an increase in cell surface FasR expression. Up-regulation of FasR with lower doses of TXT rendered cells susceptible to FasR agonist antibody-mediated apoptosis. In the absence of TXT, anti-FasR antibodies were completely without effect, suggesting that TXT is critical for priming apoptosis mediated through the Fas pathway. In addition, gap-junctional intercellular communication was augmented by TXT in SGC1 cells concomitant with increased connexin43 expression and membrane localization.

Conclusions: We have identified several novel targets of TXT that contribute to its antitumor activity in poorly differentiated salivary gland carcinoma. These results suggest that TXT may be appropriate for additional in vivo studies and clinical trials in patients with salivary cancers.




This article has been cited by other articles:


Home page
Arch Otolaryngol Head Neck SurgHome page
G. H. Yoo, G. Subramanian, M. P. Piechocki, J. F. Ensley, O. Kucuk, O. E. Tulunay, F. Lonardo, H. Kim, J. Won, T. Stevens, et al.
Effect of Docetaxel on the Surgical Tumor Microenvironment of Head and Neck Cancer in Murine Models
Arch Otolaryngol Head Neck Surg, July 1, 2008; 134(7): 735 - 742.
[Abstract] [Full Text] [PDF]


Home page
Arch Otolaryngol Head Neck SurgHome page
G. H. Yoo, G. Subramanian, R. R. Boinpally, A. Iskander, N. Shehadeh, J. Oliver, W. Ezzat, M. P. Piechocki, J. F. Ensley, H.-S. Lin, et al.
An In Vivo Evaluation of Docetaxel Delivered Intratumorally in Head and Neck Squamous Cell Carcinoma
Arch Otolaryngol Head Neck Surg, May 1, 2005; 131(5): 418 - 429.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. H. Yoo, M. P. Piechocki, J. F. Ensley, T. Nguyen, J. Oliver, H. Meng, D. Kewson, T. Y. Shibuya, F. Lonardo, and M. A. Tainsky
Docetaxel Induced Gene Expression Patterns in Head and Neck Squamous Cell Carcinoma Using cDNA Microarray and PowerBlot
Clin. Cancer Res., December 1, 2002; 8(12): 3910 - 3921.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.